Clover Health Investments, Corp.

Clover Health Investments, Corp. (CLOV) Market Cap

Clover Health Investments, Corp. has a market capitalization of $1.27B.

Financials based on reported quarter end 2025-12-31

Price: $2.48

-0.01 (-0.60%)

Market Cap: 1.27B

NASDAQ · time unavailable

CEO: Andrew Toy

Sector: Healthcare

Industry: Medical - Healthcare Plans

IPO Date: 2020-06-12

Website: https://www.cloverhealth.com

Clover Health Investments, Corp. (CLOV) - Company Information

Market Cap: 1.27B · Sector: Healthcare

Clover Health Investments, Corp. operates as a medicare advantage insurer in the United States. The company through its Clover Assistant, a software platform that provides preferred provider organization and health maintenance organization health plans for medicare-eligible consumers. It also focuses on non-insurance businesses. Clover Health Investments, Corp. was incorporated in 2014 and is based in Franklin, Tennessee.

Analyst Sentiment

43%
Sell

Based on 9 ratings

Analyst 1Y Forecast: $3.00

Average target (based on 3 sources)

Consensus Price Target

Low

$2

Median

$3

High

$6

Average

$3

Potential Upside: 34.0%

Price & Moving Averages

Loading chart...

📘 Full Research Report

ℹ️

AI-Generated Research: This report is for informational purposes only.

📘 CLOVER HEALTH INVESTMENTS CORP CLA (CLOV) — Investment Overview

🧩 Business Model Overview

Clover Health Investments Corp (CLOV) operates as a next-generation healthcare technology company with a primary focus on improving health outcomes for America’s seniors. The company functions as a Medicare Advantage insurer, combining insurance operations with advanced data analytics and machine learning through its proprietary software platform, the Clover Assistant. This platform serves as a decision support tool for primary care physicians, aiming to facilitate more preventive and personalized patient care. Clover differentiates itself with a mission to democratize access to healthcare by reducing costs and enhancing the quality of care for traditionally underserved populations, particularly in regions that suffer from primary care shortages and socioeconomic disparities.

💰 Revenue Streams & Monetisation Model

Clover Health’s revenue is predominantly derived from its Medicare Advantage insurance premium collections. The company receives fixed monthly premiums from the Centers for Medicare & Medicaid Services (CMS) for each enrolled member, adjusted based on risk scores and clinical profiles. This capitated model aligns incentives around preventive care and chronic disease management. Additionally, the company recognizes revenue through its Direct Contracting Entity (DCE) operations—serving beneficiaries under Medicare’s value-based payment models—where the company assumes financial risk for total healthcare spending of attributed populations. Ancillary sources of potential revenue include partnerships with providers for data analytics and population health tools, though these remain nascent relative to insurance-related cash flows.

🧠 Competitive Advantages & Market Positioning

Clover Health’s most prominent competitive advantage lies in its technology-first approach, epitomized by the Clover Assistant. By integrating comprehensive patient data from claims, labs, prescriptions, and electronic health records, the Assistant provides actionable insights at the point of care and supports primary care physicians in clinical decision-making. This data-driven approach seeks to reduce unnecessary medical costs and improve outcomes by enabling earlier interventions. Clover’s emphasis on serving underserved markets—often overlooked by legacy insurers due to lower density or higher risk—has enabled it to carve out a distinctive presence in the Medicare Advantage market. The direct engagement with physicians, coupled with a streamlined user experience relative to legacy platforms, further differentiates its positioning against large, incumbent payers.

🚀 Multi-Year Growth Drivers

Multiple structural tailwinds support CLOV’s long-term growth outlook. The U.S. Medicare-eligible population continues to expand as baby boomers age into retirement, simultaneously increasing the total addressable market for Medicare Advantage plans. The ongoing shift from fee-for-service to value-based care and capitated insurance models further aligns policy and industry incentives with the company’s care-delivery structure. Clover’s technology fosters scalability, enabling geographical expansion with relatively lower incremental costs compared to traditional payers. Increased physician adoption of the Clover Assistant not only potentially enhances medical outcomes but also fortifies member retention and satisfaction, driving organic growth. Additionally, Clover’s entry and expansion into direct contracting and its potential for offering analytics as a service create adjacent growth pathways beyond its core insurance business.

⚠ Risk Factors to Monitor

Clover Health faces several substantive risks inherent to its operating environment. The company is exposed to medical cost risk and requires careful management of the medical loss ratio; unanticipated increases in claim costs (such as those from adverse selection, pandemics, or misestimated risk scores) may materially impact profitability. Regulatory changes in Medicare Advantage reimbursement rates, risk adjustment mechanisms, or value-based care policy can affect revenue and operating margins. As a younger insurer competing against entrenched national payers, Clover must continually invest in branding, physician engagement, and market development to build scale. Technological execution risk exists with the ongoing development and adoption of the Clover Assistant platform. Furthermore, reliance on government programs with fixed pricing introduces challenges around margin expansion versus peers operating in commercial insurance.

📊 Valuation & Market View

Clover Health is evaluated within a framework that balances its multi-year growth potential against operational execution and industry risks. The company is generally valued on a price-to-sales or enterprise value-to-revenue basis, reflecting its growth-phase financials and trajectory toward operating profitability. Market sentiment toward Medicare Advantage upstarts is influenced by perceived sustainability of growth, demonstrated medical cost management, unit economic trends, and the ability to scale technology adoption. Compared to larger, diversified insurers, CLOV typically trades at a valuation discount or premium depending on investor confidence in its path to profitability, breadth of membership growth, and progress in scaling its technology-driven value proposition.

🔍 Investment Takeaway

Clover Health Investments Corp represents a disruptive approach to Medicare Advantage and value-based care, differentiating itself by leveraging advanced analytics and technology to improve healthcare for traditionally underserved populations. Its scalable, physician-facing platform addresses inefficiencies in primary care, offering a compelling value proposition for both members and providers. However, the company operates in a challenging regulatory environment, with evolving reimbursement structures and intense competition from established insurers. Sustained success for Clover will depend on operational execution, continued physician and member adoption, proficiency in medical cost management, and consistency in translating technology investments into measurable clinical and financial outcomes. CLOV is best viewed as a high-risk, high-reward play on the digital transformation of U.S. healthcare delivery.

⚠ AI-generated — informational only. Validate using filings before investing.

Fundamentals Overview

Loading fundamentals overview...

📊 AI Financial Analysis

Powered by StockMarketInfo
Earnings Data: Q Ending 2025-12-31

"Clover Health (CLOV) reported revenue of $487.7M for the year ending December 31, 2025, but experienced a net loss of $49.3M. The company's earnings per share (EPS) stands at -0.0954. Total assets are valued at $541.0M against total liabilities of $232.3M, resulting in total equity of $308.7M. The balance sheet indicates a healthy net debt position of -$78.3M, suggesting cash reserves exceeding liabilities. However, operational cash flow is negative at -$68.2M, alongside free cash flow of -$68.7M, reflecting challenges in cash generation. Performance metrics are concerning, showing a 1-year price change of -52.23%, with significant declines observed over both six months and year-to-date at -44.00% and -24.48%, respectively. The company does not currently pay dividends. Despite maintaining a price target consensus of $3, the negative performance signals caution for potential investors."

Revenue Growth

Fair

Revenue of $487.7M indicates a solid base but lacks growth context.

Profitability

Neutral

Negative net income and EPS reflect ongoing challenges in achieving profitability.

Cash Flow Quality

Neutral

Substantial negative cash flows impact financial stability.

Leverage & Balance Sheet

Positive

Strong balance sheet with net debt suggests manageable financial risk.

Shareholder Returns

Neutral

Significant price decline over the past year indicates poor shareholder returns.

Analyst Sentiment & Valuation

Caution

Stable price target of $3, but negative market performance raises concerns.

Disclaimer:This analysis is AI-generated for informational purposes only. Accuracy is not guaranteed and this does not constitute financial advice.

Clover’s Q4 and full-year 2025 results show strong top-line and membership momentum (+38% MA members to ~140k; Q4 insurance revenue $486M, +47% YoY) while keeping medical cost discipline relatively intact (ex-pharmacy cost trend 5% YoY) and delivering full-year adjusted EBITDA profitability ($22M) and adjusted net income ($20M). However, investors are seeing margin volatility: the call addressed a ~150 bps YoY step-down in gross profit margin as a cohort-mix/dilution effect driven by outsized AEP new growth (+53%). Management remains confident that new member profitability will improve as cohorts mature into year 2, with returning member contribution profit holding at $200 PMPM and new member contribution loss at $145 PMPM. For 2026, guidance is explicit: GAAP net income breakeven to $20M, consolidated gross profit $470M–$510M, adjusted EBITDA $50M–$70M, and adjusted SG&A leverage of ~100–150 bps YoY. Net-net, the story is durable cohort economics plus technology-driven engagement, but near-term margin optics are still being shaped by rapid new growth.

AI IconGrowth Catalysts

  • Reestablished market-leading Medicare Advantage membership growth while absorbing first-year new-member dilution
  • Deepening Clover Assistant engagement (approx. 2/3 of members receiving Clover Assistant-powered care in 2025)
  • Focusing 2026 annual growth on core markets where Clover Assistant PCP penetration is highest
  • Intra-year 2026 growth shift toward more cost-efficient acquisition channels
  • Market/plan tailwinds: 2026 4-star payment year for PPO plans (approx. 97% of members in wide-network PPO)
  • Counterpart Health ramp: expansion of total lives under Counterpart Assistant (near-term goal equals to current Clover Assistant patient volume)

Business Development

  • Counterpart Health / Counterpart Assistant technology expansion (bringing similar number of patients under Counterpart Assistant as under Clover Assistant inside MA plan)

AI IconFinancial Highlights

  • Q4 2025 insurance revenue: $486M (+47% YoY)
  • Full-year 2025 insurance revenue: $1.9B (+41% YoY); total revenue +40% YoY
  • Medicare Advantage membership: +38% YoY to ~140,000 members at year-end
  • Medical cost trend (excluding pharmacy) controlled at 5% YoY
  • Seasonal Part D pressure tied to IRA changes; improved Part D margin YoY
  • Full-year adjusted EBITDA profitability achieved (and full-year adjusted net income $20M; adjusted EBITDA $22M)
  • Returning member contribution profit: $200 PMPM YoY stable/strong
  • New member contribution loss improved to $145 PMPM (vs prior period expectation), reflecting better execution/benefit design despite utilization
  • Insurance segment BER: 90.9% (+970 bps YoY); normalized BER +~700 bps YoY driven by new member dilution and incremental quality investments
  • Consolidated gross profit introduced as primary guidance/reporting metric: replaced Insurance segment BER; full-year 2025 consolidated gross profit $356M
  • Q4 adjusted SG&A: $98M slightly above expectations (higher commissions + stronger-than-expected new sales + quality investments for 2026 margins)
  • Adjusted SG&A as % of revenue: 20% in Q4 (+560 bps YoY improvement); 17% full-year (+410 bps YoY improvement)
  • Gross profit margin question (from analyst): stepping down ~150 bps YoY; company response attributed to new cohort dilution/volume mix being large (~53% AEP growth), despite confidence in improvement as cohorts mature; considered reasonable due to growth rate/4-star year
  • 2026 guidance: MA membership avg 154,000–158,000 (+46% YoY at midpoint)
  • 2026 guidance: total revenue $2.810B–$2.920B (+49% YoY at midpoint)
  • 2026 guidance: consolidated gross profit $470M–$510M
  • 2026 guidance: target adjusted SG&A reduction of ~100–150 bps YoY as % of revenue
  • 2026 guidance: adjusted EBITDA $50M–$70M
  • 2026 guidance: net income breakeven to $20M (first full year of GAAP net income profitability)

AI IconCapital Funding

  • Ended Q4 2025 with $320M cash and investments (consolidated), including $122M at unregulated subsidiary level
  • Full-year cash flow used in operating activities: $67M (primarily working-capital timing related to membership growth)
  • No explicit buyback or debt figures disclosed in transcript

AI IconStrategy & Ops

  • Shift to consolidated gross profit (total revenue minus medical claims) replacing Insurance segment BER as the primary operating guidance metric
  • Quality investments and R&D support cohort economics and care delivery/technology
  • Targeted remediation/recovery actions for abnormal dental and DME activity experienced in 2025
  • Earlier care management via Clover Assistant; emphasizes encounter-based claims-linked documentation
  • Product/market: remain largest individual non-special needs plan, PPO plan, in New Jersey; scale supports efficiencies and attractiveness to partners across network
  • Counterpart platform strategy: expand total lives and deepen clinician adoption; framed as long-term growth engine alongside MA

AI IconMarket Outlook

  • 2026 guidance disclosed with numeric ranges: membership 154,000–158,000 avg; revenue $2.810B–$2.920B; consolidated gross profit $470M–$510M; adjusted SG&A % reduction 100–150 bps YoY; adjusted EBITDA $50M–$70M; GAAP net income breakeven to $20M
  • 2026 assumed tailwinds referenced: 4-star payment year for PPO (approx. 97% members in wide network PPO) and favorable impact from 2026 Part C final rate notice
  • 2027: company supports policy direction aligning payment to documented clinical care (unlinked chart review records concept); notes potential switcher data gap risk adjustment could be mitigated by CMS data sharing

AI IconRisks & Headwinds

  • Analyst-observed gross profit margin decline of ~150 bps YoY attributed to large new cohort dilution from ~53% AEP growth (expects improvement as cohorts mature into year 2/3+)
  • 2025 elevated industry utilization and intra-year new member growth created pressure; company absorbed near-term dilution because it retains full underwriting risk
  • Part D seasonal pressure related to IRA changes (mitigated by improved Part D margin YoY)
  • CMS risk adjustment linking/interoperability: company flagged oversight—CMS may not provide sufficient data for switchers entering from other MA plans; expects CMS to close gap (execution/policy dependency)
  • Dependence on stars/rate dynamics for tailwinds: relies on 2026 4-star for PPO plans and Part C final rate notice (not stated as fully hedged, though company argues structural independence from rates/stars)

Sentiment: MIXED

Note: This summary was synthesized by AI from the CLOV Q4 2025 earnings transcript. Financial data is complex; please verify all metrics against official SEC filings before making investment decisions.

Loading financial data and tables...
📁

SEC Filings (CLOV)

© 2026 Stock Market Info — Clover Health Investments, Corp. (CLOV) Financial Profile